Author

R. D. Kennedy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

E. E. Parkes· 2 shared C. Graham· 1 shared D. Griffin· 1 shared D. I. Johnston· 1 shared D. P. Harkin· 1 shared E. Gilmore· 1 shared E. M. Barros· 1 shared F. A. Sidi· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. E. Parkes

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer

E. E. Parkes, M. P. Humphries, E. Gilmore, F. A. Sidi, V. Bingham, S. M. Phyu, S. G. Craig, C. Graham, J. Miller, D. Griffin, R. D. Kennedy, S. F. Bakhoum, S. McQuaid, M. Salto-Tellez, N. E. Buckley

The paper identifies perinuclear STING (pnSTING) in ER+ breast cancer as a prognostic marker linked to immune infiltration and poor outcomes in low pnSTING tumors.

bioRxiv · Jul 23, 2020Cancer Biology

Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation

R. D. A. Wilkinson, N. McCabe, E. E. Parkes, E. M. Barros, D. I. Johnston, R. Ali, K. Lappin, R. Greenberg, D. P. Harkin, S. A. McIntosh, R. D. Kennedy, K. I. Savage

This study shows topo-II inhibitors like doxorubicin induce cGAS-STING dependent inflammation, cytokine production, and immune checkpoint activation in cancer cells, enhancing potential for immune checkpoint blockade therapy.

bioRxiv · Oct 24, 2019 · PreprintCancer Biology